Teva Pharmaceutical Industries has been granted marketing authorization by the European Commission for Cinqaero (reslizumab), an asthma therapy, in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein,and Iceland. Cinqaero is a humanized interleukin-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Cinqaero is expected to become commercially available by prescription to patients in Europe within the coming months. The product is currently approved and marketed in the US and Canada as Cinqair injection with pending regulatory approvals in other global markets.

Source: Teva Pharmaceutical Industries